新闻

On March 30, 2026, PHR shares fell 27%, losing $3.03 per share, after Phreesia cut its fiscal 2027 revenue outlook to $510-$520 million from a prior range of $545-$559 million. The lead plaintiff deadline is July 13, 2026. The Promise: December 8, 2025 When Phreesia introduced fiscal 2027 guidance on December 8, 2025, the lawsuit contends management painted an optimistic picture: The action claims these projections led shareholders to purchase PHR stock at prices reflecting growth that was not materializing. The Reality: March 30, 2026 Approximately 112 days later, after introducing fiscal 2027 guidance, Phreesia lowered its fiscal 2027 revenue guidance to $510-$520 million. Management cited "worsening visibility" and "weaker pharmaceutical marketing commitments" within its Network Solutions segment and that clients were committing lower spend levels for the second half of fiscal 2027 than management had anticipated only three months earlier. The Numbers: Promised vs. Actual Speak with an attorney about recovering your investment losses or call (212) 363-7500. What the Lawsuit Alleges About the Gap "Companies that make specific promises to investors about future performance have an obligation to disclose known risks to those projections. The gap between Phreesia's December guidance and its March revision raises important questions about what was known and when." -- Joseph E. Levi, Esq. Join the Phreesia recovery action or contact Joseph E. Levi, Esq. at (212) 363-7500. ABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report. The last day to move for lead plaintiff is July 13, 2026. Frequently Asked Questions About the PHR Lawsuit Q: What specific misstatements does the PHR lawsuit allege? A: The complaint alleges Phreesia made materially false or misleading statements regarding its fiscal 2027 revenue growth projections and the durability of pharmaceutical marketing commitments in its Network Solutions segment. When the true state was revealed on March 30, 2026, the stock price declined 27%. Q: How much did PHR stock drop? A: Shares fell approximately 27%, a decline of $3.03 per share, after Phreesia disclosed significantly reduced fiscal 2027 revenue guidance and attributed the shortfall to worsening visibility in pharmaceutical marketing commitments. Q: What if I already sold my PHR shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate. Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. You submit a claim form to receive your portion of recovery. Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs. Q: Can I join a different law firm's lawsuit instead? A: Multiple firms often file competing complaints. The court consolidates and appoints a single lead counsel. Contacting Levi & Korsinsky before July 13, 2026 ensures your losses are considered. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 27th Floor New York, NY 10004 [email protected] Tel: (212) 363-7500 Fax: (212) 363-7171 Market News and Data brought to you by Benzinga APIs To add Benzinga News as your preferred source on Google, click here.

LKQ shareholders absorbed cumulative per-share declines of $7.28, $5.53, $4.87, and $6.88 across four separate corrective disclosures between April 2024 and July 2025. The window to apply for lead plaintiff closes on June 22, 2026. February 27, 2023: The $2.1 Billion Acquisition Announcement LKQ announced a definitive agreement to acquire Uni-Select for approximately $2.1 billion, including its U.S. subsidiary FinishMaster. The company represented the deal carried "minimal integration risk" and would "enhance LKQ's business and drive profitable growth." What investors were not told, the lawsuit contends, is that FinishMaster was already losing key customers. July 27, 2023: Management Publicly Commits to $55 Million in Synergies On the Q2 2023 earnings call, management expressed being "highly confident" in achieving $55 million of cost synergies over three years. The complaint alleges that by this date, with the acquisition closing days later on August 1, defendants had full visibility into FinishMaster's deteriorating customer base yet said nothing. April 23, 2024: First Guidance Cut and CEO Departure LKQ surprised the market by cutting fiscal 2024 guidance, attributing the reduction to slowing North American demand. The company simultaneously announced CEO Dominick Zarcone's departure. LKQ stock fell $7.28 per share, or 14.9%. Yet defendants reassured investors the deal "was the right thing to do long term" and that "additional synergies" had been uncovered. July 25, 2024: Second Revenue Miss Deepens Concerns LKQ missed the reduced revenue targets set just one quarter earlier and further lowered fiscal year guidance. Shares dropped another $5.53, or 12.4%. As alleged in the action, management again attributed weakness to broad demand trends rather than disclosing FinishMaster's customer attrition. October 24, 2024: FinishMaster Customer Losses Finally Disclosed The company admitted that FinishMaster had been losing major customers to competitors, with losses beginning "pre-acquisition or pre-closing." This revelation, the filing states, contradicted over a year of public statements portraying the integration as on track. April 24, 2025: $200 Million Revenue Shortfall Revealed LKQ's Wholesale North America segment missed quarterly revenue targets by approximately $200 million and EBITDA margin targets by $24 million. Shares fell $4.87, or 11.6%. July 24, 2025: Continued Margin Deterioration Confirmed The company reported another EBITDA miss of approximately $20 million, with an 11% year-over-year margin decline driven by competitors undercutting LKQ on price. Shares dropped $6.88, or 17.8%. Timeline of Alleged Disclosure Failures Submit your claim before the deadline or call (212) 363-7500. "Timely disclosure of material developments is fundamental to fair and efficient markets. The chronology here raises serious questions about the gap between what was known internally and what was shared with the investing public," stated Joseph E. Levi, Esq. Act now to protect your rights or contact Joseph E. Levi, Esq. at (212) 363-7500. ABOUT THE FIRM -- For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years. Those wishing to serve as lead plaintiff must act by June 22, 2026. Frequently Asked Questions About the LKQ Lawsuit Q: When did LKQ Corporation allegedly mislead investors? A: The class period runs from February 27, 2023 to July 23, 2025. The alleged fraud was revealed through a series of corrective disclosures beginning April 23, 2024 and continuing through July 24, 2025, each causing significant stock declines. Q: How much did LKQ stock drop? A: Shares suffered four separate declines of $7.28 (14.9%), $5.53 (12.4%), $4.87 (11.6%), and $6.88 (17.8%) as concealed problems with the FinishMaster acquisition were progressively revealed. Q: Who is eligible to join the LKQ investor lawsuit? A: Investors who purchased LKQ stock or securities between February 27, 2023 and July 23, 2025 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares. Q: What if I already sold my LKQ shares? Can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate. Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. You submit a claim form to receive your portion of recovery. Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 27th Floor New York, NY 10004 [email protected] Tel: (212) 363-7500 Fax: (212) 363-7171 Market News and Data brought to you by Benzinga APIs To add Benzinga News as your preferred source on Google, click here.